13th European AIDS Conference

October 12-15, 2011 - Belgrade, Serbia

EACS 2011: Switching from Efavirenz to Rilpivirine Single Tablet Regimen Is Safe and Effective

People with undetectable viral load who switched from the efavirenz/tenofovir/emtricitabine Atripla single tablet regimen to the new rilpivirine/tenofovir/emtricitabine Eviplera coformulation (marketed as Complera in the U.S.) maintained full viral suppression, researchers reported at the 13th European AIDS Conference (EACS 2011) last week in Belgrade.alt

Read more:

EACS 2011: IL28B Gene Variant that Helps Hepatitis C Treatment May Hinder HIV Treatment

A common variant in a gene that doubles the chance of hepatitis C treatment working in people coinfected with HIV may also nearly double the risk of death in patients taking antiretroviral therapy (ART), according to a report at the 13th European AIDS Conference (EACS 2011) last week in Belgrade.alt

Read more:

EACS 2011: Incidence of Non-AIDS Malignancies Stabilizes in D:A:D Study, but Prognosis Improves

Occurrence of non-AIDS-defining cancer has remained stable in recent years, according to an analysis of the large D:A:D observational cohort presented at the 13th European AIDS Conference (EACS 2011) last week in Belgrade. Prognosis for HIV positive people with such malignancies remains poor, but appears to have improved somewhat over time.alt

Read more:

EACS 2011: Antiretroviral Therapy Reduces Liver Fibrosis Progression in HIV/HCV Coinfected People

Earlier initiation of antiretroviral therapy (ART) and spending more time on HIV treatment may help slow liver disease progression in HIV/HCV coinfected patients, according to an Italian study using non-invasive methods presented at the 13th European AIDS Conference (EACS 2011) last week in Belgrade.alt

Read more:

EACS 2011: Dolutegravir Highly Effective, Twice-daily Works Better for Integrase-resistant HIV Patients

The novel integrase inhibitor dolutegravir is among the most potent antiretroviral agents studied to date, but treatment-experienced individuals with raltegravir resistance need to take it twice-daily in order to achieve optimal concentrations, according to findings presented at the 13th European AIDS Conference (EACS 2011) this week in Belgrade.alt

Read more: